![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: EID2B |
Gene summary for EID2B |
![]() |
Gene information | Species | Human | Gene symbol | EID2B | Gene ID | 126272 |
Gene name | EP300 interacting inhibitor of differentiation 2B | |
Gene Alias | EID-2B | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q96D98 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
126272 | EID2B | PTC05 | Human | Thyroid | PTC | 1.79e-08 | 2.54e-01 | 0.2065 |
126272 | EID2B | PTC07 | Human | Thyroid | PTC | 1.28e-06 | 1.40e-01 | 0.2044 |
126272 | EID2B | ATC12 | Human | Thyroid | ATC | 3.98e-03 | 4.83e-02 | 0.34 |
126272 | EID2B | ATC13 | Human | Thyroid | ATC | 7.21e-44 | 7.69e-01 | 0.34 |
126272 | EID2B | ATC2 | Human | Thyroid | ATC | 1.97e-05 | 5.60e-01 | 0.34 |
126272 | EID2B | ATC4 | Human | Thyroid | ATC | 6.08e-04 | 7.03e-02 | 0.34 |
126272 | EID2B | ATC5 | Human | Thyroid | ATC | 2.65e-46 | 8.25e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000751716 | Thyroid | ATC | muscle organ development | 139/6293 | 327/18723 | 4.45e-04 | 2.64e-03 | 139 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
EID2B | SNV | Missense_Mutation | rs761187141 | c.265N>C | p.Glu89Gln | p.E89Q | Q96D98 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
EID2B | SNV | Missense_Mutation | novel | c.50G>A | p.Ser17Asn | p.S17N | Q96D98 | protein_coding | tolerated(0.09) | possibly_damaging(0.556) | TCGA-C5-A8XJ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
EID2B | SNV | Missense_Mutation | c.349N>T | p.Arg117Cys | p.R117C | Q96D98 | protein_coding | deleterious(0.03) | probably_damaging(0.999) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
EID2B | SNV | Missense_Mutation | novel | c.350N>A | p.Arg117His | p.R117H | Q96D98 | protein_coding | deleterious(0.05) | probably_damaging(0.998) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
EID2B | SNV | Missense_Mutation | novel | c.392C>T | p.Ala131Val | p.A131V | Q96D98 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
EID2B | SNV | Missense_Mutation | novel | c.362N>G | p.Phe121Cys | p.F121C | Q96D98 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-EO-A3AV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | CR |
EID2B | SNV | Missense_Mutation | novel | c.308N>T | p.Ser103Ile | p.S103I | Q96D98 | protein_coding | tolerated(0.08) | benign(0.04) | TCGA-WX-AA46-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
EID2B | SNV | Missense_Mutation | c.343G>C | p.Glu115Gln | p.E115Q | Q96D98 | protein_coding | deleterious(0.03) | probably_damaging(0.971) | TCGA-CN-4723-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |